BR0010080A - Inibidores de renina - Google Patents

Inibidores de renina

Info

Publication number
BR0010080A
BR0010080A BR0010080-3A BR0010080A BR0010080A BR 0010080 A BR0010080 A BR 0010080A BR 0010080 A BR0010080 A BR 0010080A BR 0010080 A BR0010080 A BR 0010080A
Authority
BR
Brazil
Prior art keywords
renin inhibitors
glaucoma
restenosis
diseases
compounds
Prior art date
Application number
BR0010080-3A
Other languages
English (en)
Other versions
BR0010080B1 (pt
Inventor
Volker Breu
Hans-Peter Maerki
Eric Vieira
Wolfgang Wostl
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0010080A publication Critical patent/BR0010080A/pt
Publication of BR0010080B1 publication Critical patent/BR0010080B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Patente de Invenção: "INIBIDORES DE RENINA". A presente invenção refere-se a um composto da fórmula (I) em que R^ 1^, R^ 2^ e R^ 3~ são como definidos na descrição e reivindicações e seus sais farmaceuticamente aceitáveis. Os compostos são úteis para o tratamento de doenças que estão associadas com restenose, glaucoma, infarto cardíaco, alta pressão sang³ínea e perda de órgão terminal, por exemplo, insuficiência cardíaca e insuficiência dos rins.
BRPI0010080-3A 1999-04-27 2000-04-19 inibidores de renina BR0010080B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99108199 1999-04-27
PCT/EP2000/003555 WO2000064873A1 (en) 1999-04-27 2000-04-19 Renin inhibitors

Publications (2)

Publication Number Publication Date
BR0010080A true BR0010080A (pt) 2002-01-15
BR0010080B1 BR0010080B1 (pt) 2012-03-20

Family

ID=8238050

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0010080-3A BR0010080B1 (pt) 1999-04-27 2000-04-19 inibidores de renina

Country Status (35)

Country Link
US (2) US6376672B1 (pt)
EP (1) EP1175400B1 (pt)
JP (1) JP3808706B2 (pt)
KR (1) KR100443684B1 (pt)
CN (1) CN1147471C (pt)
AR (2) AR018719A1 (pt)
AT (1) ATE512949T1 (pt)
AU (1) AU763718B2 (pt)
BR (1) BR0010080B1 (pt)
CA (1) CA2370888C (pt)
CO (1) CO5170513A1 (pt)
CZ (1) CZ302012B6 (pt)
DK (1) DK1175400T3 (pt)
EG (1) EG23979A (pt)
ES (1) ES2366668T3 (pt)
GC (1) GC0000251A (pt)
HK (1) HK1045999B (pt)
HR (1) HRP20010762A2 (pt)
HU (1) HU227764B1 (pt)
IL (2) IL146002A0 (pt)
JO (1) JO2256B1 (pt)
MA (1) MA26787A1 (pt)
MX (1) MXPA01010934A (pt)
MY (1) MY127894A (pt)
NO (1) NO320803B1 (pt)
NZ (1) NZ514981A (pt)
PE (1) PE20010069A1 (pt)
PL (1) PL199895B1 (pt)
PT (1) PT1175400E (pt)
RS (1) RS51156B (pt)
RU (1) RU2213731C2 (pt)
TR (1) TR200103095T2 (pt)
TW (1) TWI224593B (pt)
WO (1) WO2000064873A1 (pt)
ZA (1) ZA200108735B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376672B1 (en) * 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
US6835686B2 (en) * 2001-07-05 2004-12-28 Millennium Specialty Chemicals Catalyst system and process for rearrangement of epoxides to allylic alcohols
RU2005102002A (ru) * 2002-06-27 2005-09-20 Актелион Фармасьютиклз Лтд. (Ch) Новые производные тетрагидропиридина
US20040214832A1 (en) * 2003-04-10 2004-10-28 Cuiman Cai Piperazine derivative renin inhibitors
JP2007523845A (ja) * 2003-04-29 2007-08-23 アクテリオン　ファマシューティカルズ　リミテッド 新規３，４−ジ置換１，２，３，６−テトラヒドロピリジン誘導体
TW200900399A (en) * 2003-10-01 2009-01-01 Speedel Experimenta Ag Organic compounds
AR045950A1 (es) * 2003-10-09 2005-11-16 Speedel Experimenta Ag Compuestos derivados de piperazina, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos.
US20050209141A1 (en) * 2003-10-17 2005-09-22 Silver Randi B Mast cell-derived renin
CN1906163A (zh) 2003-11-26 2007-01-31 诺瓦提斯公司 作为肾素抑制剂的4－苯基哌啶衍生物
AR053406A1 (es) * 2004-07-09 2007-05-09 Speedel Experimenta Ag Derivados de piperidina como inhibidores de renina. composiciones farmaceuticas
ES2384637T3 (es) 2004-10-08 2012-07-10 Novartis Ag Uso de inhibidores de la renina para la prevención o el tratamiento de disfunción diastólica o insuficiencia cardiaca diastólica
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
GB0500784D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
EP1707202A1 (de) * 2005-03-31 2006-10-04 Speedel Experimenta AG Organische Verbindungen
TW200722424A (en) 2005-03-31 2007-06-16 Speedel Experimenta Ag Substituted piperidines
EP1897879A3 (en) * 2005-03-31 2008-06-11 Speedel Experimenta AG 2,4,5-substituted piperidines as renin inhibitors
BRPI0609534A2 (pt) * 2005-03-31 2010-04-13 Speedel Experimenta Ag piperidinas 3,4,5-substituìdas
ES2352564T3 (es) * 2005-03-31 2011-02-21 Novartis Ag Piperidinas sustituidas.
TW200716622A (en) * 2005-03-31 2007-05-01 Speedel Experimenta Ag Substituted piperidines
GEP20115206B (en) 2005-05-27 2011-04-26 Actelion Pharmaceuticals Ltd Novel piperidine carboxylic acid amide derivatives
GB0514203D0 (en) * 2005-07-11 2005-08-17 Novartis Ag Organic compounds
JP2009512715A (ja) * 2005-10-21 2009-03-26 ノバルティス アクチエンゲゼルシャフト レニン阻害剤と抗異脂肪血症剤および／または抗肥満症剤の組み合わせ
CN101356156B (zh) * 2005-11-14 2012-12-05 生命医药公司 天冬氨酸蛋白酶抑制剂
BRPI0620736A2 (pt) * 2005-12-30 2011-12-20 Novartis Ag compostos orgánicos
EP1816122A3 (en) * 2006-01-19 2007-09-19 Speedel Experimenta AG 3,4,5-substituted piperidines as therapeutic compounds
TW200804359A (en) * 2006-01-19 2008-01-16 Speedel Experimenta Ag Substituted 4-phenylpiperidines
TW200821303A (en) * 2006-08-08 2008-05-16 Speedel Experimenta Ag Organic compounds
WO2008021552A2 (en) * 2006-08-18 2008-02-21 Duke University Biased ligands and methods of identifying same
EP1911758A1 (en) * 2006-10-04 2008-04-16 Speedel Experimenta AG Phenyl piperidine derivatives for use as renin inhibitors
EP1908761A1 (en) * 2006-10-04 2008-04-09 Speedel Experimenta AG Organic compounds
SG182223A1 (en) 2007-06-25 2012-07-30 Novartis Ag N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors
EA201000720A1 (ru) * 2007-11-02 2010-10-29 Новартис Аг 4,4-дизамещённые пиперидины как ингибиторы ренина
US10517839B2 (en) 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
EP2488661B1 (en) 2009-10-14 2014-12-24 Oberbauer, Rainer Acute kidney injury risk testing
WO2013045505A1 (en) 2011-09-28 2013-04-04 Novartis Ag Biomarkers for raas combination therapy
EP2810644A1 (en) 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4868181A (en) * 1986-08-04 1989-09-19 E. I. Du Pont De Nemours And Company 1,4-dihydropyridine derivatives with calcium agonist and alpha1 -antagonist activity
DK231088D0 (da) 1988-04-28 1988-04-28 Ferrosan As Piperidinforbindelser, deres fremstilling og anvendelse
DE3640475A1 (de) 1986-11-27 1988-06-09 Hoechst Sa Lab Arzneimittel auf basis von derivaten des 3,4-diphenylpiperidins, die verwendung der derivate als arzneimittel sowie neue 3,4-diphenylpiperidinderivate und verfahren zu ihrer herstellung
DE69119098T2 (de) 1991-06-24 1996-10-31 Optische Ind De Oude Delft Nv Vorrichtung zur beobachtung der atmung
AU6735396A (en) 1995-07-24 1997-02-18 Railfix N.V. Electrical permanent-magnet system for manoeuvring a magnetic, particularly a ferromagnetic, load
TR199800409T1 (xx) * 1995-09-07 1998-05-21 F.Hoffmann-La Roche Ag Kalp ve b�brek yetersizli�inin tedavii�in yeni 4-(oksialkoksifenil)-3-oksi-piperidinler
WO1999012532A2 (en) * 1997-09-08 1999-03-18 F.Hoffmann-La Roche Ag Piperidine derivatives against malaria
US6376672B1 (en) * 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors

Also Published As

Publication number Publication date
KR20010109529A (ko) 2001-12-10
YU77101A (sh) 2004-09-03
TWI224593B (en) 2004-12-01
HUP0203669A2 (hu) 2003-02-28
NO20015206L (no) 2001-10-25
MY127894A (en) 2006-12-29
HK1045999A1 (en) 2002-12-20
CA2370888C (en) 2005-08-23
IL146002A (en) 2007-03-08
NO20015206D0 (no) 2001-10-25
US6673931B2 (en) 2004-01-06
ZA200108735B (en) 2003-01-23
AR018719A1 (es) 2001-11-28
HU227764B1 (en) 2012-02-28
HK1045999B (zh) 2004-10-21
HUP0203669A3 (en) 2003-12-29
ES2366668T3 (es) 2011-10-24
CZ20013854A3 (cs) 2002-04-17
WO2000064873A1 (en) 2000-11-02
CA2370888A1 (en) 2000-11-02
JO2256B1 (en) 2004-10-07
AU763718B2 (en) 2003-07-31
NZ514981A (en) 2004-02-27
ATE512949T1 (de) 2011-07-15
DK1175400T3 (da) 2011-07-18
CN1147471C (zh) 2004-04-28
JP3808706B2 (ja) 2006-08-16
PE20010069A1 (es) 2001-03-03
HRP20010762A2 (en) 2005-02-28
GC0000251A (en) 2006-11-01
MXPA01010934A (es) 2002-05-06
US20020087002A1 (en) 2002-07-04
PL199895B1 (pl) 2008-11-28
PT1175400E (pt) 2011-08-11
TR200103095T2 (tr) 2002-04-22
IL146002A0 (en) 2002-07-25
JP2002543063A (ja) 2002-12-17
EG23979A (en) 2008-02-27
CN1349503A (zh) 2002-05-15
US6376672B1 (en) 2002-04-23
NO320803B1 (no) 2006-01-30
AU4296800A (en) 2000-11-10
BR0010080B1 (pt) 2012-03-20
EP1175400A1 (en) 2002-01-30
AR070473A2 (es) 2010-04-07
CZ302012B6 (cs) 2010-09-08
MA26787A1 (fr) 2004-12-20
PL353442A1 (en) 2003-11-17
CO5170513A1 (es) 2002-06-27
RU2213731C2 (ru) 2003-10-10
EP1175400B1 (en) 2011-06-15
RS51156B (sr) 2010-10-31
KR100443684B1 (ko) 2004-08-09

Similar Documents

Publication Publication Date Title
BR0010080A (pt) Inibidores de renina
BR0010076A (pt) Inibidores de renina
BR0014179A (pt) Modernos derivados de ácido aminodicarboxìlico com propriedades farmacêuticas
BR0208373A (pt) Inibidores da tirosina cinase
BRPI0416989A (pt) derivados aminopirazole como inibidores gsk-3
BR0316081A (pt) Derivados de 2-piridona como inibidores de elastase de neutrófilo
BR0309012A (pt) Uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para a preparação de um composto
SE0202462D0 (sv) Novel use
BRPI0312464B8 (pt) compostos inibidores de tirosina quinases, composições farmacêuticas compreendendo os mesmos, processos para fabricação e usos dos mesmos
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
WO2006067165A3 (en) Indolidone derivatives for the treatment or prevention of fibrotic diseases
BR0214342A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
BR0209821A (pt) Compostos, processo para a manufatura desses compostos, composições farmacêuticas que compreendem os mesmos, processo para o tratamento e/ou profilaxia de enfermidades e utilização dos compostos
BRPI0411863A (pt) derivados de pirazolil-indol como inibidores de cinase, processo para seu preparo e composições farmacêuticas compreendendo os mesmos
BRPI0416628A (pt) uso de compostos orgánicos
BR0214386A (pt) Método para identificação de enzimas de objetivação a tumor
BR0212158A (pt) Derivados de diarilcicloalquila, processos para a sua preparação e sua aplicação como ativadores de ppar
BR0317572A (pt) Benzoxazinas e seus derivados como inibidores de pi3ks
BRPI0111591B8 (pt) composto, composição farmacêutica, e, usos de um composto
BR0111383A (pt) Benezenos 1,2,4-tri-substituìdos como inibidores de 15-lipoxigenase
BRPI0409498A (pt) uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para preparação de um composto
GT199900015A (es) Procedimiento para tratar la insuficiencia cardiaca
BRPI0513379A (pt) derivados de sulfonamida
DK1641454T3 (da) Pyrazolo[3,4-B]pyridin-6-oner som GSK-3-hæmmere
BR9914929A (pt) Fenil - alquenoil - guanidinas substituìdas de ácido biliar, processos para a sua preparação, sua aplicação como medicamentos ou agentes diagnósticos, assim como medicamento contendo as mesmas

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11, 13, 24 E 25 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/03/2012, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE AS 14A E 15A ANUIDADES.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.